Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

Recruiting now · Phase 2/Phase 3

Conditions studied: Generalized Pustular Psoriasis

In brief

This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).

Key facts

Study ID

NCT06477536

Run by

Shanghai Huaota Biopharmaceutical Co., Ltd.

People needed

33

Starts

2024-09-02

Expected to finish

2026-06-30

Last updated by the study team

2025-02-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients participated in the preceding placebo-controlled Phase 2 study （HB0034-04）and completed at least the Week 12 visit of the HB0034-04 study
• Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment
• Men and women of reproductive age who have no parenting plans and are willing to use reliable contraception during the study period and for 6 months after the last dose of the study drug;
• Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules

You may not qualify if…

• Patients who are experiencing GPP flare

Where it is running

• Peking University People's Hospital (PKUPH) — Beijing, China (enrolling)
• Peking University People's Hospital — Beijing, China (enrolling)
• The Second affiliated Hospital zhejiang University School of Medicine — Hangzhou, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.